ReviewEpilepsy currents2025
How Soon is Soon Enough? Consideration of Timing and Disease Etiology for microRNAs in Epilepsy.
Review in Epilepsy currents, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Recurrent spontaneous seizures in epilepsy cause a myriad of structural, circuit-related, and molecular modifications in the brain. The multifaceted molecular changes suggest that wide-reaching epigenetic mechanisms are altered in epilepsy. Indeed, it has been known for more than 15 years that a class of epigenetic regulators called microRNAs-short, noncoding RNAs that control the translation and stability of sometimes hundreds of mRNA targets-are dysregulated after seizures and in epilepsy in human patients and rodent models. Epilepsy-associated microRNAs regulate many different molecular contributors to epilepsy, including ion channels, neuroinflammatory modulators, and proteins critical for neuronal and synaptic structure. In recent years, it has become clear that microRNAs are important at every phase of epilepsy-from the onset of the first seizure to the latent phase and chronic epilepsy. In line with these findings, manipulation of a subset of microRNAs has been shown to alter seizure susceptibility, reduce epileptogenesis, and/or decrease the frequency of spontaneous recurrent seizures in animal models of epilepsy. These studies illustrate the promise of microRNAs as future therapeutic targets in epilepsy and show that specific microRNAs play different regulatory roles depending on the phase and type of epilepsy. In this concise review, we summarize recent findings of microRNAs in epilepsy, emphasizing novel approaches that advance the field. We discuss the insight on underlying mechanisms and disease etiology that can be drawn from these studies and highlight the importance of timing when developing microRNA-based therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.